Thyroid Cancer

  • Jennifer S. Yu
  • Joy Coleman
  • Jeanne Marie Quivey


Thyroid cancer is rare - 1% of malignancies and 0.2% of cancer deaths in the US. Incidence is increasing, which may, in part, be related to increased detection of subclinical disease by extensive use of ultrasound and FNA. Female:male ratio of 3:1. Incidence begins increasing in teenage years, peaking in the fifth decade. Prior radiation exposure is the main environmental factor linked to development. It can result in benign (goiter, nodular disease) and malignant thyroid disease. Radiation induced tumors are usually well-differentiated and behave similar to spontaneous thyroid cancer. Periodic clinical and biochemical testing (serum thyroglobulin) is prudent for those who have undergone prior thyroid irradiation (including incidental irradiation during mantle or head and neck radiation). No evidence to support increased incidence of medullary or anaplastic thyroid cancer in patients previously exposed to radiation.


Thyroid Cancer Papillary Thyroid Carcinoma Regional Lymph Node Metastasis Medullary Thyroid Cancer Anaplastic Thyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



  1. Brierley J, Tsang R, Panzarella T, et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 2005;63(4):418-427.CrossRefGoogle Scholar
  2. Chen J, Tward J, Shrieve DC, et al. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008: 460-464.Google Scholar
  3. Chow SM, Law SCK, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. IJROBP 2002;52(3):784-795.Google Scholar
  4. Foote RL, Brown PD, Garces YI, et al. Is there a role for radiation therapy in the management of Hurthle cell carcinoma? Int J Radiat Oncol Biol Phys 2003;56(4):1067-1072.PubMedCrossRefGoogle Scholar
  5. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144(6):980-987.PubMedCrossRefGoogle Scholar
  6. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103(7):1330-1335.PubMedCrossRefGoogle Scholar
  7. Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer- local disease control in the modern era. Head Neck 2008;30:883-888.PubMedCrossRefGoogle Scholar

Further Reading

  1. Biermann M, Pixberg MK, Schuck A, Heinecke A, Kopcke W, Schmid KW, Dralle H, Willich N, Schober O. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin. 2003;42(6):244-250.Google Scholar
  2. Fraker DL, Skarulis M, Livolsi V. Thyroid Tumors. In: Davita VT, Hellman S, and Rosenberg SA, editors. Cancer: Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 1740-1763.Google Scholar
  3. Leenhardt L, Grosclaude P, Cherie-Challine L; Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14(12):1056-1060.Google Scholar
  4. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257(1):50-59.Google Scholar
  5. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115(2):237-243.Google Scholar
  6. NCCN Physician Guidelines. Accessed May 8, 2009.
  7. Posner MD, Quivey JM, Akazawa PF, et al. Dose optimization for the treatment of anaplastic thyroid carcinoma: a comparison of treatment planning techniques. Int J Radiat Oncol Biol Phys 2000;48:475-483.PubMedCrossRefGoogle Scholar
  8. Reynolds RM, Weir J, Stockton DL, Brewster DH, et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 2005;62(2):156-162.CrossRefGoogle Scholar
  9. Rosenbluth BD, Serrano V, Happersett L, et al. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 2005;63(5):1419-1426.PubMedCrossRefGoogle Scholar
  10. Swift PS, Larson S, Price DC. Cancer of the Thyroid. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 757-778.Google Scholar
  11. Tsang RW, Brierly JD. The Thyroid. In: Cox JD, Ang KK, editors. Radiation oncology: Rationale, techniques, results. 8th ed. St. Louis: Mosby; 2003. pp. 310-330.Google Scholar
  12. Tubiana M. Role of radioiodine in the treatment of local thyroid cancer. Int J Radiat Oncol Biol Phys 1996;36(1):263-265.PubMedCrossRefGoogle Scholar
  13. Wilson PC, Millar BM, Brierley JD. The management of advanced thyroid cancer. Clin Oncol (R Coll Radiol) 2004;16(8):561-568.CrossRefGoogle Scholar
  14. Yutan E, Clark OH. Hurthle cell carcinoma. Curr Treat Options Oncol 2001;2(4):331-335.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Jennifer S. Yu
    • 1
  • Joy Coleman
    • 2
  • Jeanne Marie Quivey
    • 1
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Radiation OncologyElmhurst Memorial HospitalElmhurstUSA

Personalised recommendations